Aliases:This biomarker is also known as:
- collagenase type IV-A,
- matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase),
- EC 220.127.116.11,
- neutrophil gelatinase,
- matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase),
- Matrix metalloproteinase-2,
- matrix metalloproteinase-II,
- 72 kDa gelatinase,
- 72 kDa type IV collagenase,
- Gelatinase A,
MMP2 is a member of the matrix metalloproteinase (MMP) family and is involved in many functions, such as remodeling of the vasculature, angiogenesis, tissue repair and remodeling, tumor invasion, inflammation, atherosclerotic plaque rupture, reproduction and embryonic development, as well as in disease processes such as arthritis and metastasis. In addition to degrading extracellular matrix proteins, MMP2 can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction and appears to have a role in myocardial cell death pathways. MMPs are generally secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. The MMP2 protein degrades gelatin type I and collagen types IV, V, VII, and X. MMP2 gene mutations have been associated with Winchester syndrome and Nodulosis-Arthropathy-Osteolysis (NAO) syndrome. There are two known isoforms of this gene, encoded by two transcript variants.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
No additional data available.
Ninety biomarkers were measured using a series of multiplexed immunoassays and results analyzed by the EDRN data management center splitting the cases and controls into training and validation sets, excluding subjects with DCIS or atypical hyperplasia from the training phase. We found little evidence that any of these markers can discriminate women with invasive cancer from those with benign breast conditions.
MMP2 alone was not shown to be a strong predictor of ovarian cancer.
Of the ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. MMP2 alone was not a strong predictor.
No associated publications found.
- HGNC entry for MMP2 from Genenames
- KEGG entry for MMP2 from Genome.jp
- Entrez entry for MMP2 all NCBI Databasese
- Human GEO Profiles for MMP2 from NCBI GEO Profiles
- Human Geo Datasets containing term MMP2 from NCBI GEO Datasets
- GWAS Study Datasets containing gene MMP2 from GWAS
- Human Single Nucleotide Polymorphisms info for MMP2
- Human Gene(s) with 'MMP2' as Gene Name/Alias
- Human Gene RefSeq for MMP2 from NCBI
- UniProtKB/Swiss-Prot entry for MMP2 from Uniprot
- Human Protein RefSeq for MMP2 from NCBI
- FDA web page describing approval of MMP2
No other associated resources found.
|UniProt Accession #:||P08253|
|Mutated Sites Count:||261|
|Associated Pubmed ID Count||25|
|Affected Protein Function Sites Count:||5|